These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 22085578)

  • 1. [A woman with palmar and plantar hyperpigmentation].
    van Tienhoven G; Wilmink JW
    Ned Tijdschr Geneeskd; 2011; 155(45):A4100. PubMed ID: 22085578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Capecitabine-induced hyperpigmentation].
    Vázquez-Bayo C; Rodríguez-Bujaldón AL; Jiménez-Puya R; Galán-Gutiérrez M; Moreno-Giménez JC
    Actas Dermosifiliogr; 2007 Sep; 98(7):491-3. PubMed ID: 17669305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capecitabine-induced hand-foot syndrome and cutaneous hyperpigmentation in an elderly vitiligo patient.
    Tavares-Bello R
    J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1434-5. PubMed ID: 17958867
    [No Abstract]   [Full Text] [Related]  

  • 4. Focal acral hyperpigmentation in a patient undergoing chemotherapy with capecitabine.
    Villalón G; Martín JM; Pinazo MI; Calduch L; Alonso V; Jordá E
    Am J Clin Dermatol; 2009; 10(4):261-3. PubMed ID: 19489659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palmar-plantar hyperpigmentation with capecitabine in adjuvant colon cancer.
    Vickers MM; Easaw JC
    J Gastrointest Cancer; 2008; 39(1-4):141-3. PubMed ID: 19440857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
    Yoshimoto N; Yamashita T; Fujita T; Hayashi H; Tsunoda N; Kimura M; Tsuzuki N; Yamashita H; Toyama T; Kondo N; Iwata H
    Breast Cancer; 2010 Oct; 17(4):298-302. PubMed ID: 19789949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of capecitabine-induced hyperpigmentation and radiation recall phenomenon.
    Ghosal N; Misra V
    Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):632. PubMed ID: 19304468
    [No Abstract]   [Full Text] [Related]  

  • 8. [Capecitabine-induced hyperpigmentation followed by hand-foot syndrome: a new case report].
    Agharbi FZ; Meziane M; Benhemmne H; Daoudi K; Elmesbahi O; Mikou O; Mernissi FZ
    Ann Dermatol Venereol; 2012 Mar; 139(3):221-2. PubMed ID: 22401689
    [No Abstract]   [Full Text] [Related]  

  • 9. Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome?
    Do JE; Kim YC
    Clin Exp Dermatol; 2007 Sep; 32(5):519-21. PubMed ID: 17509060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of low-dose capecitabine monotherapy for metastatic breast cancer.
    Taguchi T; Nakayama T; Masuda N; Yoshidome K; Akagi K; Nishida Y; Yoshikawa Y; Ogino N; Abe C; Sakamoto J; Noguchi S;
    Chemotherapy; 2010; 56(2):166-70. PubMed ID: 20407245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hand-foot syndrome with capecitabine therapy].
    Marini A; Hengge UR
    Hautarzt; 2007 Jun; 58(6):532-6. PubMed ID: 16897045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acral and palmo-plantar hyperpigmentation in a patient with disseminated hepatocellular carcinoma.
    Goyal R; Chalamalasetty SB; Madan K; Paul SB; Arora R; Safaya R; Acharya SK
    Indian J Gastroenterol; 2007; 26(6):292-3. PubMed ID: 18431015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased mast cell density in capecitabine-induced hand-foot syndrome: a new pathologic finding.
    Latif S; Fraga G; Gadzia J
    J Drugs Dermatol; 2010 Mar; 9(3):268-70. PubMed ID: 20232590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment].
    Risum S; Langer SW
    Ugeskr Laeger; 2003 Aug; 165(33):3161-2. PubMed ID: 12968412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A case of severe hand-foot syndrome caused by capecitabine].
    Shimomatsuya T; Mitsudou Y; Nakamura T; Yonezawa K; Shiraishi S; Fujino M; Maruhashi K
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1139-41. PubMed ID: 17637558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hand and foot syndrome secondary to capecitabine.
    Lal HS
    Indian J Dermatol Venereol Leprol; 2014; 80(5):427-30. PubMed ID: 25201844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer.
    Chua D; Wei WI; Sham JS; Au GK
    Jpn J Clin Oncol; 2008 Apr; 38(4):244-9. PubMed ID: 18407933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine and hand-foot syndrome.
    Saif MW
    Expert Opin Drug Saf; 2011 Mar; 10(2):159-69. PubMed ID: 21174613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
    Chalermchai T; Tantiphlachiva K; Suwanrusme H; Voravud N; Sriuranpong V
    Asia Pac J Clin Oncol; 2010 Sep; 6(3):155-60. PubMed ID: 20887495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
    Caronia D; Martin M; Sastre J; de la Torre J; García-Sáenz JA; Alonso MR; Moreno LT; Pita G; Díaz-Rubio E; Benítez J; González-Neira A
    Clin Cancer Res; 2011 Apr; 17(7):2006-13. PubMed ID: 21325291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.